Switching Drug Class After Initial SSRI Failure
J Clin Psychiatry 1997;58(7):326-326 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Sir: The report by Joffe et al. underscores an important issue
for the practicing psychiatrist, namely, the appropriate next
step for the nonresponder to a serotonin selective reuptake inhibitor
(SSRI) antidepressant. Their data from an open-label,
non-placebo-controlled database review showed that 51% of
patients responded to a second SSRI after experiencing lack of
efficacy with their initial SSRI. This response represents an important
question to be assessed in controlled trials, and the authors
acknowledge that the lack of a placebo-controlled design
limits their conclusions.